AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
- Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack
- Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
- Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound
- Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
Research & Development
- A promising treatment for an incurable, deadly kidney disease
- Existing drug could treat aggressive brain cancer
- New drug may protect against memory loss in Alzheimer's disease
- Experimental validation confirms the ability of artificial intelligence to accelerate drug discovery
- Breast cancer can form 'sleeper cells' after drug treatment
- A new drug could revolutionize the treatment of neurological disorders
- Interactions discovered in cells insulating nerve pathways
Conferences & Events
- SMi's Inaugural Pharmaceutical Manufacturing & Cleanroom Technology Conference
- Disruptive Technologies in Pharma 2019
- Respiratory Drug Delivery 2019
- Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference
- eyeforpharma The Marketing Disruption Summit
- Optima to host post-conference workshop at Lyophilization USA
- The need for a blueprint emergency plan to avoid a HPAPI crisis
Regulatory Affairs
- FDA approves first treatment for patients with rare type of lung disease
- EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US
- FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
- FDA approves first therapy for rare joint tumor
- FDA approves first treatment for severe hypoglycemia that can be administered without an injection